-M Varella-Garcia Researcher Activity Profile

Research Author Detailed Information 

M Varella-Garcia Publication Rate By Year

M Varella-Garcia has published 3 paper(s) in 2006, 8 paper(s) in 2007, 8 paper(s) in 2008, for a total of 19 research publications in total.

M M Varella-Garcia Author Information

LAST NAME: varella-garcia

FIRST NAME: M

INITIALS: m

AFFILIATION:

Papers

M Varella-Garcia's Publication Record

1. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Year Published: 2007
Division of Medical Oncology, Department of Medicine, University of Colorado Health Sciences Center and Cancer Center, Aurora, CO 80010, USA.
2. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Year Published: 2008
Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy. federico.cappuzzo@humanitas.it
3. Adult lung side population cells have mesenchymal stem cell potential. Year Published: 2008
Division of Cardiology, Cardiovascular Pulmonary Laboratory, Denver, Colorado, USA.
4. Adult lung side population cells have mesenchymal stem cell potential. Year Published: 2008
Division of Cardiology, Cardiovascular Pulmonary Laboratory, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
5. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Year Published: 2006
Department of Craniofacial Biology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, USA.
6. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Year Published: 2006
Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA. Britta.Jacobsen@uchsc.edu
7. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Year Published: 2006
Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA.
8. Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Year Published: 2007
Department of Medicine, Pulmonary Sciences and Critical Care Division, University of Colorado Health Sciences Center, Denver, CO 80262, USA. robert.stearman@uchsc.edu
9. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Year Published: 2007
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
10. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. Year Published: 2007
Department of Hematology-Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy. federico.cappuzzo@humanitas.it
11. EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Year Published: 2007
Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA.
12. Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. Year Published: 2007
Department of Medicine, School of Medicine, University of Colorado, Denver Health Sciences Center, Denver, Colorado, USA.
13. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. Year Published: 2007
Department of Hematology-Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy. federico.cappuzzo@humanitas.it
14. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. Year Published: 2007
Department of Hematology-Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy. federico.cappuzzo@humanitas.it
15. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Year Published: 2008
Department of Medicine/Medical Oncology, University of Colorado Health Sciences Center, Campus Box 6511, Mail Box 8117, Aurora, CO 80045. marileila.garcia@uchsc.edu.
16. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Year Published: 2008
Department of Medicine/Medical Oncology, University of Colorado Health Sciences Center, Campus Box 6511, Mail Box 8117, Aurora, CO 80045, USA.
17. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Year Published: 2008
Department of Medicine/Medical Oncology, University of Colorado Health Sciences Center, Campus Box 6511, Mail Box 8117, Aurora, CO 80045, USA.
18. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Year Published: 2008
Department of Obstretrics and Gynecology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA.
19. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Year Published: 2008
Department of Obstretrics and Gynecology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA.